Study guide

1.1 Hematopoiesis, Bone Marrow Microenvironment & Growth Factors

ASCP Hematology Technologist Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Hematopoiesis & Cellular Physiology

1.1 Hematopoiesis, Bone Marrow Microenvironment & Growth Factors 1.2 Erythrocyte Physiology, Metabolism & Destruction Pathways 1.3 Leukocyte Kinetics, Morphology & Phagocytic Function 1.4 Platelet Physiology, Ultrastructure & Thrombopoiesis

2 Chapter 2: Erythrocyte Disorders & Non-Hemolytic Anemias

2.1 Iron Metabolism & Iron Deficiency Anemia 2.2 Anemia of Chronic Inflammation, Sideroblastic Anemias & Lead Toxicity 2.3 Hemoglobinopathies & Qualitative Globin Chain Defects 2.4 Alpha and Beta Thalassemias 2.5 Megaloblastic, Macrocytic & Hypoproliferative Anemias

3 Chapter 3: Hemolytic Anemias & Erythrocytosis

3.1 Intrinsic Hemolytic Anemias: Membrane & Metabolic Defects 3.2 Immune-Mediated Hemolytic Anemias & Paroxysmal Nocturnal Hemoglobinuria 3.3 Non-Immune Extrinsic Hemolytic Anemias & Microangiopathies 3.4 Polycythemia & Erythrocytosis Classification

4 Chapter 4: Benign Leukocyte Alterations, Acute Leukemias & Bone Marrow Evaluation

4.1 Quantitative Leukocyte Alterations, Toxic Change & Leukemoid Reaction 4.2 Inherited Leukocyte Anomalies, Reactive Lymphocytosis & Storage Disorders 4.3 Acute Myeloid Leukemia (AML) & Related Neoplasms 4.4 Acute Lymphoblastic Leukemia (ALL) & Precursor Lymphoid Neoplasms 4.5 Bone Marrow Examination, Differential & M:E Ratio Assessment

5 Chapter 5: Chronic Myeloid Neoplasms, MDS & Mature Lymphoid Neoplasms

5.1 Myelodysplastic Syndromes (MDS) & Overlap Syndromes 5.2 Chronic Myeloproliferative Neoplasms (CML, PV, ET, PMF) 5.3 Chronic Lymphocytic Leukemia & Indolent B-Cell Lymphomas 5.4 Aggressive Lymphomas, Hodgkin Lymphoma & Mature T-Cell Disorders 5.5 Plasma Cell Neoplasms & Monoclonal Gammopathies

6 Chapter 6: Hemostasis: Primary, Secondary & Fibrinolytic Systems

6.1 Primary Hemostasis, Platelet Receptors & Qualitative Platelet Disorders 6.2 Quantitative Platelet Disorders & Immune Thrombocytopenias 6.3 The Coagulation Cascade & Cell-Based Hemostatic Model 6.4 Fibrinolytic System, Natural Anticoagulants & Thrombophilia

7 Chapter 7: Factor Deficiencies, Coagulation Testing & Anticoagulation

7.1 Hereditary Coagulation Factor Deficiencies & von Willebrand Disease 7.2 Acquired Coagulation Factor Deficiencies, Circulating Inhibitors & DIC 7.3 Routine and Specialized Coagulation Testing & Mixing Study Interpretation 7.4 Anticoagulant Therapies, Laboratory Monitoring & Reversal Strategies 7.5 Viscoelastic Testing, Heparin Neutralization & Chromogenic Assays

8 Chapter 8: Hematology Laboratory Testing & Advanced Diagnostics

8.1 Automated Hematology Analyzers, Interference Flags & Manual Methods 8.2 Cytochemical Staining, Flow Cytometry & Molecular Diagnostics 8.3 Erythrocyte Sedimentation Rate, Hemolytic Indicators & Special Erythrocyte Studies 8.4 Cerebrospinal Fluid Analysis, Cell Counts & Cytology 8.5 Serous Effusions & Synovial Fluid Analysis

9 Chapter 9: Laboratory Operations, Quality Assessment & Safety

9.1 The Total Testing Process: Preanalytical, Analytical & Postanalytical Quality 9.2 Quality Control Statistics, Levey-Jennings Charts & Westgard Multirules 9.3 Laboratory Mathematics: Dilutions, Concentration, Molarity & Standard Curves 9.4 Method Evaluation, Diagnostic Statistics & Point-of-Care Testing 9.5 Regulatory Framework, Proficiency Testing & Competency Assessment 9.6 Laboratory Safety: Bloodborne Pathogens, Personal Protective Equipment & Chemical Hygiene 9.7 Emergency Response, Spill Management & Specimen Packaging and Transport 9.8 Hematology Instrumentation: Microscopy, Counters, Analyzers & Centrifuges

1.1 Hematopoiesis, Bone Marrow Microenvironment & Growth Factors

Key Takeaways Explain This Topic AI

Pluripotent hematopoietic stem cells (HSCs) are immunophenotypically characterized as CD34+, CD38-, Lin-, CD133+, and CD117+ (c-Kit), exhibiting lifelong self-renewal and multilineage differentiation capacity.

Ontogeny of hematopoiesis transitions across three sequential anatomical phases: Mesoblastic (yolk sac, synthesizing embryonic hemoglobins Gower 1, Gower 2, and Portland), Hepatic (fetal liver peak at 4–5 months, synthesizing HbF), and Medullary (bone marrow cavity from month 5 onward, transitioning to adult HbA and HbA2).

Adult hematopoietic red marrow is restricted to the axial skeleton and proximal epiphyses of long bones; expected normal bone marrow cellularity is calculated as (100 - Patient Age) ± 10%.

The marrow microenvironment is divided into the endosteal niche (osteoblasts maintaining HSC quiescence via Jagged-1/Notch and Angiopoietin-1/Tie-2) and the vascular niche (CAR cells and sinusoidal endothelium directing proliferation and egress via CXCL12/CXCR4 chemokine tethers).

Early-acting cytokines (SCF, FLT3-L, IL-3) expand primitive progenitors, whereas lineage-specific growth factors (EPO, TPO, G-CSF, M-CSF, IL-5, IL-7) drive terminal maturation via JAK-STAT and MAPK signaling pathways; normal adult marrow M:E ratio is 1.5:1 to 3.0:1.

Last updated: August 2026

Hematopoiesis, Bone Marrow Microenvironment & Growth Factors

Hematopoiesis is the continuous, highly regulated physiological process responsible for the formation, proliferation, differentiation, and terminal maturation of all blood cell lineages. In healthy adults, the hematopoietic system generates approximately 10 11 to 10 12 10^{11}\text{ to }10^{12} 1 0 11 to 1 0 12 new blood cells per day to replenish senescent mature cells in the peripheral circulation and respond dynamically to physiological stress, infection, or blood loss.

Hematopoietic Stem Cell Biology & Immunophenotype

At the apex of the hematopoietic hierarchy sits the pluripotent hematopoietic stem cell (HSC) . HSCs represent a rare population accounting for less than 0.01% of total nucleated bone marrow cells. HSCs are characterized by two cardinal properties:

Self-Renewal: The capacity to undergo asymmetric or symmetric cell division without differentiation, thereby preserving the stem cell reservoir throughout an individual's lifetime.

Multipotency / Pluripotency: The developmental plasticity to generate every mature cellular lineage in the peripheral blood under the orchestration of specific microenvironmental signals and lineage-restricted cytokines. [ Pluripotent HSC ]

  • (CD34+, CD38-, Lin-, CD133+)
  • │
  • ▼
  • [ Multipotent Progenitor ]
  • (MPP)
  • │
  • ┌─────────────────┴─────────────────┐
  • ▼ ▼
  • [ Common Myeloid Progenitor ] [ Common Lymphoid Progenitor ]
  • (CMP) (CLP)
  • │ │
  • ┌────────────┼────────────┐ ┌──────────┼──────────┐
  • ▼ ▼ ▼ ▼ ▼ ▼
  • [CFU-GEMM] [CFU-Eo] [CFU-Baso] [Pre-T] [Pre-B] [Pro-NK]
  • │ │ │ │ │ │
  • ┌───┴───┐ │ │ ▼ ▼ ▼
  • ▼ ▼ ▼ ▼ T-Cells B-Cells NK-Cells
  • BFU-E CFU-GM Eosinophils Basophils
  • │ │
  • ▼ ┌───┴───┐
  • RBCs ▼ ▼
  • Neut Mono
  • Immunophenotypic Markers of HSCs and Progenitors

Flow cytometric identification and quantification of stem cells rely on precise cell-surface cluster of differentiation (CD) antigens:

CD34: A 110 kDa transmembrane sialomucin expressed on primitive pluripotent HSCs, multipotent progenitors, and early committed blast cells. In clinical stem cell transplantation, an apheresis graft yield of ≥ 2.0 × 10 6 to 5.0 × 10 6 CD34+ cells/kg \ge 2.0 \times 10^6\text{ to }5.0 \times 10^6\text{ CD34+ cells/kg} ≥ 2.0 × 1 0 6 to 5.0 × 1 0 6 CD34+ cells/kg of recipient body weight is the minimum threshold required for sustained hematopoietic engraftment.

CD38 Negative ( C D 38 − CD38^- C D 3 8 − ): CD38 is an early marker of lineage commitment. True, primitive long-term culture-initiating HSCs lack CD38 ( C D 38 − CD38^- C D 3 8 − ); expression of CD38 marks transition to committed progenitor pools.

Lineage Negative ( L i n − Lin^- L i n − ): Uncommitted stem cells lack mature lineage-specific markers: CD3 (T-lymphocytes), CD19 and CD20 (B-lymphocytes), CD14 (monocytes), CD15 and CD66b (granulocytes), CD56 (natural killer cells), and CD235a / Glycophorin A (erythroid cells).

CD133 (Prominin-1): A 5-transmembrane domain glycoprotein co-expressed exclusively on primitive stem cells, disappearing as cells differentiate.

CD117 (c-Kit): Receptor tyrosine kinase that binds Stem Cell Factor (SCF); expressed on HSCs, myeloid progenitors, mast cells, and early erythroblasts.

CD90 (Thy-1): Co-expressed on early primitive stem cells ( C D 34 + C D 38 − L i n − C D 90 + C D 133 + CD34^+CD38^-Lin^-CD90^+CD133^+ C D 3 4 + C D 3 8 − L i n − C D 9 0 + C D 13 3 + ).

Lineage Commitment Hierarchy

The pluripotent HSC gives rise to the Multipotent Progenitor (MPP) , which loses lifelong self-renewal capacity and subsequently bifurcates into two principal progenitor branches:

Common Myeloid Progenitor (CMP): Differentiates into the colony-forming unit granulocyte, erythrocyte, monocyte, and megakaryocyte ( CFU-GEMM ), which yields:

Erythroid Series: Burst-Forming Unit-Erythroid ( BFU-E ) → \rightarrow → Colony-Forming Unit-Erythroid ( CFU-E ) → \rightarrow → Pronormoblast.

Megakaryocytic Series: BFU-Meg → \rightarrow → CFU-Meg → \rightarrow → Megakaryoblast.

Granulocyte-Monocyte Series: CFU-GM → \rightarrow → CFU-G (neutrophilic lineage) and CFU-M (monocytic/macrophage lineage).

Eosinophil & Basophil Series: CFU-Eo and CFU-Baso.

Common Lymphoid Progenitor (CLP): Gives rise to pro-T cells (migrate to the thymus), pro-B cells (mature in bone marrow), Natural Killer (NK) cell progenitors, and lymphoid dendritic cells.

Ontogeny of Hematopoiesis: Developmental Phases

During human embryonic and fetal development, hematopoiesis transitions through three distinct, temporally overlapping anatomical phases:

Phase Primary Anatomical Site Gestational Timing Dominant Hemoglobin Synthesized Primary Cell Lineages Produced

Mesoblastic (Primitive) Yolk sac blood islands 2nd to 10th gestational week Gower 1 ( ζ 2 ϵ 2 \zeta_2\epsilon_2 ζ 2 ​ ϵ 2 ​ ), Gower 2 ( α 2 ϵ 2 \alpha_2\epsilon_2 α 2 ​ ϵ 2 ​ ), Portland ( ζ 2 γ 2 \zeta_2\gamma_2 ζ 2 ​ γ 2 ​ ) Primitive, large, nucleated megaloblasts; no granulocytes or platelets

Hepatic (Definitive) Fetal liver (primary); fetal spleen and thymus (secondary) 5th week through birth (peaks at 4–5 months) Fetal Hemoglobin (HbF, α 2 γ 2 \alpha_2\gamma_2 α 2 ​ γ 2 ​ ) (approx. 90% of total) Definitive enucleated erythrocytes, granulocytes, monocytes, megakaryocytes

Medullary / Myeloid Bone marrow medullary cavities Begins at month 5; primary site from month 6 through adult life Transition to Adult Hemoglobin A (HbA, α 2 β 2 \alpha_2\beta_2 α 2 ​ β 2 ​ ) ( ≈ 60 – 80 % \approx 60\text{--}80\% ≈ 60 – 80% at birth) and HbA2 ( α 2 δ 2 \alpha_2\delta_2 α 2 ​ δ 2 ​ ) Full multilineage hematopoiesis (erythroid, myeloid, megakaryocytic, lymphoid) % Total Hematopoiesis

  • 100 │ Yolk Sac Fetal Liver Bone Marrow
  • 80 │ /────────\ /───────────\ /─────────────
  • 60 │ / \ / \ /
  • 40 │ / \ / \ /
  • 20 │ / X \ /
  • 0 └──┴─────────────┴─┴─────────────────┴───┴────────────────
  • 1 2 3 4 5 6 7 8 9 Birth Adult
  • Gestational Months
  • Adult Anatomical Distribution and Cellularity Formula

In infants and young children, active hematopoiesis occupies virtually all skeletal cavities ( red marrow ). Between ages 5 and 18, centripetal marrow regression occurs: active red marrow is progressively replaced by inactive adipose tissue ( yellow marrow ), starting in the distal phalanges and moving proximally through long bones.

Adult Active Sites: Confined to the axial skeleton (pelvis/iliac crest, sternum, vertebrae, ribs, skull, scapulae) and the proximal epiphyses of the femurs and humeri.

Bone Marrow Biopsy Sites: The posterior superior iliac spine (PSIS) of the pelvis is the standard, safest anatomical site for bone marrow aspiration and trephine core biopsy. The sternum can be used for aspirates only in adults ( > 18 >18 > 18 years), but sternal core biopsy is absolutely contraindicated due to the catastrophic risk of mediastinal, cardiac, or aortic puncture.

Normal Cellularity Calculation: Cellularity represents the ratio of hematopoietic cells to adipocytes in a core biopsy section: Expected Normal Marrow Cellularity (%) = ( 100 − Patient Age ) ± 10 % \text{Expected Normal Marrow Cellularity (\%)} = (100 - \text{Patient Age}) \pm 10\% Expected Normal Marrow Cellularity (%) = ( 100 − Patient Age ) ± 10%

Example: An 80-year-old patient has an expected normal cellularity of ( 100 − 80 ) ± 10 % = 20 % ± 10 % (100 - 80) \pm 10\% = 20\% \pm 10\% ( 100 − 80 ) ± 10% = 20% ± 10% (range: 10 % to 30 % 10\%\text{ to }30\% 10% to 30% ).

Bone Marrow Microenvironment & Specialized Niche Architecture

The bone marrow microenvironment (stroma) provides the specialized structural matrix, adhesion molecules, and localized biochemical cues required for stem cell maintenance, self-renewal, proliferation, and differentiation.

Stromal Elements and Extracellular Matrix

Cellular Components: Adventitial reticular cells, sinusoidal endothelial cells (forming the blood-marrow barrier), osteoblasts, osteoclasts, adipocytes, and specialized marrow macrophages (e.g., nurse cells in erythroblastic islands).

Extracellular Matrix (ECM): Collagens (types I, III, IV), fibronectin, laminin, vitronectin, and proteoglycans (heparan sulfate). These macromolecules anchor hematopoietic progenitors and sequester growth factors to present them directly to stem cell receptors.

  • Endosteal Niche vs. Vascular Niche [ ENDOSTEAL (OSTEOBLASTIC) NICHE ]
  • Location: Inner cortical bone surface
  • Key Cells: Osteoblasts, osteoclasts
  • Key Molecules: Jagged-1/Notch, Angiopoietin-1/Tie-2, Osteopontin
  • Function: Maintains HSC quiescence (G0 phase), self-renewal, stemness
  • │
  • ▼ (Differentiation & Migration)
  • [ VASCULAR (SINUSOIDAL) NICHE ]
  • Location: Marrow sinusoidal capillaries & endothelial lining
  • Key Cells: CXCL12-Abundant Reticular (CAR) cells, Sinusoidal Endothelium
  • Key Molecules: CXCL12 (SDF-1), CXCR4, VCAM-1 (CD106), VLA-4 (α4β1)
  • Function: Proliferation, lineage commitment, transendothelial egress

Endosteal (Osteoblastic) Niche: Located along the inner trabecular bone surface. Osteoblasts express Jagged-1 (which binds Notch-1 on HSCs) and Angiopoietin-1 (which binds the Tie-2 receptor on HSCs). This niche maintains long-term primitive HSCs in a quiescent, non-dividing ( G 0 G_0 G 0 ​ ) state, protecting the genome from oxidative and replicative stress.

Vascular (Sinusoidal) Niche: Located adjacent to thin-walled sinusoidal capillaries. Endothelial cells and subendothelial CXCL12-Abundant Reticular (CAR) cells secrete high concentrations of CXCL12 (Stromal Cell-Derived Factor 1 / SDF-1) . CXCL12 binds the CXCR4 receptor on HSCs and myeloid progenitors, anchoring them in the proliferative compartment.

Stem Cell Mobilization Mechanisms

To harvest CD34+ HSCs from peripheral blood for autologous or allogeneic transplantation, the CXCR4–CXCL12 retention tether must be disrupted:

Recombinant G-CSF (Filgrastim / Lenograstim): Administered over 4 to 5 days, G-CSF activates marrow neutrophils and monocytes to release serine proteases ( neutrophil elastase, cathepsin G, and matrix metalloproteinase-9 [MMP-9] ). These proteases cleave CXCL12, CXCR4, VCAM-1, and c-Kit, liberating HSCs to cross sinusoidal walls into the bloodstream.

Plerixafor (AMD3100 / Mozobil): A small-molecule, reversible CXCR4 receptor antagonist . It directly blocks CXCL12 binding to CXCR4, rapidly mobilizing CD34+ cells within 4 to 9 hours.

Hematopoietic Cytokines & Growth Factor Cascades

Hematopoietic cytokines are glycoprotein growth factors that bind high-affinity transmembrane receptors on target progenitors, initiating signal transduction primarily via the Janus kinase / Signal Transducer and Activator of Transcription (JAK-STAT) and MAPK/ERK pathways to suppress apoptosis, induce cell cycle entry, and direct lineage differentiation.

Growth Factor Major Site of Synthesis Target Receptor / Cell Lineage Primary Mechanism of Action

Stem Cell Factor (SCF / c-Kit Ligand) Bone marrow stromal cells, endothelial cells CD117 (c-Kit receptor tyrosine kinase) on HSCs and progenitors Synergizes with other cytokines to promote survival and expansion of early pluripotent stem cells; non-lineage-specific.

FLT3-Ligand (FLT3-L) Marrow stroma, activated T-lymphocytes FLT3 / CD135 on early multipotent and lymphoid progenitors Synergizes with SCF and IL-3 to expand early multipotent progenitors and dendritic cell precursors.

Interleukin-3 (IL-3 / Multi-CSF) Activated T-lymphocytes Multipotent progenitors, CFU-GEMM Broad multilineage growth factor stimulating early myeloid, erythroid, and megakaryocytic progenitor survival.

Granulocyte-Macrophage CSF (GM-CSF) T-lymphocytes, macrophages, endothelial cells, fibroblasts CFU-GM, myeloblasts, monoblasts Stimulates proliferation, differentiation, and functional activation of neutrophils, monocytes, and eosinophils.

Erythropoietin (EPO) Renal peritubular interstitial cells (90%); hepatocytes (10%) EPO Receptor (EpoR) on CFU-E and Pronormoblasts Master regulator of erythropoiesis; prevents apoptosis of CFU-E; upregulated by Hypoxia-Inducible Factor 1 α \alpha α (HIF-1 α \alpha α ) in response to tissue hypoxia.

Thrombopoietin (TPO) Liver hepatocytes (constitutive primary source); proximal renal tubules c-Mpl (CD110) on HSCs, CFU-Meg, megakaryocytes, and platelets Primary regulator of megakaryocyte polyploidization, maturation, and platelet shedding; cleared from plasma via c-Mpl binding on circulating platelets.

Granulocyte CSF (G-CSF) Macrophages, endothelial cells, bone marrow fibroblasts G-CSF Receptor (CD114) on CFU-G, myelocytes, PMNs Lineage-specific driver of neutrophilic granulopoiesis, acceleration of transit time, and marrow mobilization.

Interleukin-5 (IL-5) T-helper 2 (Th2) lymphocytes, mast cells IL-5R α \alpha α (CD125) on CFU-Eo and eosinophils Lineage-specific growth factor driving eosinophil differentiation, survival, chemotaxis, and effector activation.

Interleukin-7 (IL-7) Bone marrow stroma, thymic epithelial cells IL-7R α \alpha α (CD127) on Common Lymphoid Progenitors Essential, non-redundant growth factor required for early B-cell and T-cell lymphoid lineage commitment and survival.

Bone Marrow Examination: M:E Ratio Calculation & Interpretation

The Myeloid-to-Erythroid (M:E) ratio is a critical quantitative parameter determined during a 500-cell bone marrow aspirate differential count: M:E Ratio = ∑ Granulocytic Precursors (Myeloblasts through Segmented Neutrophils) ∑ Nucleated Erythroid Precursors (Pronormoblasts through Orthochromic Normoblasts) \text{M:E Ratio} = \frac{\sum \text{Granulocytic Precursors (Myeloblasts through Segmented Neutrophils)}}{\sum \text{Nucleated Erythroid Precursors (Pronormoblasts through Orthochromic Normoblasts)}} M:E Ratio = ∑ Nucleated Erythroid Precursors (Pronormoblasts through Orthochromic Normoblasts) ∑ Granulocytic Precursors (Myeloblasts through Segmented Neutrophils) ​

Normal Adult Reference Range: 1.5 : 1 to 3.0 : 1 1.5:1\text{ to }3.0:1 1.5 : 1 to 3.0 : 1 (some references accept up to 4.0 : 1 4.0:1 4.0 : 1 ).

Cells Included in the Numerator (Myeloid): Myeloblasts, promyelocytes, neutrophilic myelocytes, neutrophilic metamyelocytes, neutrophilic bands, segmented neutrophils, eosinophils and their precursors, basophils and their precursors.

Cells Included in the Denominator (Erythroid): Pronormoblasts, basophilic normoblasts, polychromatophilic normoblasts, and orthochromic normoblasts.

Cells Excluded from Both: Monocytes, macrophages, lymphocytes, plasma cells, megakaryocytes, osteoblasts, osteoclasts, and non-hematopoietic stromal cells.

Clinical Interpretation of Altered M:E Ratios

Increased M:E Ratio ( > 4 : 1 >4:1 > 4 : 1 ):

Myeloid Hyperplasia: Reactive leukocytosis / severe bacterial infection, Chronic Myeloid Leukemia (CML), Myeloproliferative Neoplasms (MPN).

Erythroid Hypoplasia: Pure Red Cell Aplasia (PRCA), Diamond-Blackfan anemia, aplastic anemia (isolated erythroid failure).

Decreased M:E Ratio ( < 1.5 : 1 <1.5:1 < 1.5 : 1 ):

Erythroid Hyperplasia: Hemolytic anemias (compensatory response), Megaloblastic anemia (ineffective erythropoiesis), Sideroblastic anemia, Polycythemia Vera, Erythropoietin administration.

Myeloid Hypoplasia: Agranulocytosis, drug-induced marrow suppression (e.g., clozapine, chemotherapy), severe neutropenia.